The role of interdisciplinary cooperation in the prevention of Medication-Related Osteonecrosis of the Jaw (MRONJ)

Medication-Related Osteonecrosis of the Jaw (MRONJ) is considered one of the most severe complications of treatment with antiresorptive drugs. The number of patients with MRONJ has significantly increased due to the broadening of the indication to treat with bisphosphonates and other antiresorptive drugs (e.g. denosumab). Because MRONJ has a significant impact on the patients’ quality of life, it is necessary to reduce the risk of such complications by implementing preventive measures, e.g. full dental and oral cavity examination for all patients qualified for treatment with angiogenesis inhibitors or antiresorptive drugs.